Beijing CorreGene Biotechnology Co., Ltd., founded by several Peking University alumni, dedicated to the development of innovative therapeutics based on T-cell receptors (TCRs). CorreGene has ...

BIO 2026 features more than 150 sessions and 950+ speakers across 18 focus areas — from AI and digital health to diagnostics and personalized medicine, emerging opportunities in global markets, and ...

As BIO 2026 comes to a close, we look ahead to biotech's sixth decade. Pioneering patients remind us why innovation matters, and experts outline what will shape biotech's next decade, and leaders warn ...

Day 3 of BIO 2026 looked ahead to biotech's next chapter: how AI could accelerate drug discovery, why U.S. biotechnology leadership is a national security priority, and what states can do to compete ...

Patient groups happy Virginia won't have a PDAB. Plus, seeking clarity about onshoring agreements. (789 words, 3 minutes, 10 seconds) Patient advocates praised Virginia Gov. Abigail Spanberger’s veto ...

The contents of the member listings on the BIO Web site may not be reproduced or used in any form without prior written permission from BIO. For more information about members, please refer to the ...

The "Product & Company Valuation" course is designed to teach a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals, or strategic ...

On Tuesday, BIO 2026 attendees explored what it will take to maintain America's innovation edge, while a new industry report offered fresh evidence that capital is returning to the sector and emerging ...

The Prescription Drug User Fee Act (PDUFA) is a cornerstone of the U.S. regulatory framework that helps ensure patients have timely access to safe and effective new medicines. Enacted by Congress in ...